Sickle Cell Disease Clinical Trial
Official title:
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia
Patients are being asked to participate in this study because they have severe sickle cell
anemia (SCD) with or without the beta thalassemia trait. Sickle cell anemia is an illness
where the red blood cells change shape and can clog up blood vessels. This keeps the body
from getting the oxygen it needs. Thalassemia is when the body does not make enough
hemoglobin, something that helps the oxygen get to the places it needs to go in the body. The
patient may or may not need to get regular blood transfusions (getting more blood) to improve
their quality of life (feel better) and prevent organ damage (problems with the brain, heart,
lung, kidney, and gonad, for example.). The transfusions can also cause problems, including
iron overload (too much iron in the blood), which can be fatal (patients can die) without
regular deferoxamine shots. Even with the best usual treatments, people with thalassemia or
SCD die sooner. There is no proven cure.
We would like to treat patients using bone marrow transplantation, a treatment that has been
used for people with SCD. The transplant uses healthy "matched" bone marrow. This comes from
a brother or sister who does not have sickle cell disease or severe thalassemia. If the
treatment works, the sickle cell disease or thalassemia may be cured. This treatment has been
used to treat patients with sickle cell disease or thalassemia. It has worked in most cases.
We hope, but cannot promise, that the transplanted marrow will make healthy cells, and
patients will not have sickle cell disease or severe thalassemia anymore.
We do not know what effect this treatment will have on the damage that has already been done
by the disease. Finding that out is the main reason for this study. Currently, very little
has been reported about organ function after bone marrow transplants in patients with sickle
cell anemia.
Prior to any bone marrow transplant, we will need patients to:
- Answer questions about their medical history;
- Undergo a physical examination;
- Have tests done to see how well the lungs are working;
- Have a chest x-ray;
- Have an EKG to look at the heart;
- Have an MRI & MRA (Magnetic Resonance Angiography, which looks at the blood vessels and
the blood flowing through them). These 2 tests will look to see if the patient has had
any strokes;
- Have a PET scan to look at the head and body;
- Have a liver biopsy to determine if the liver has been damaged (which can happen from
iron overload that happens after many transfusions). Too much liver damage would mean a
transplant cannot be done.
For the liver biopsy, the skin is numbed with medicine, and a special needle goes into the
liver. The needle removes a very small piece of the liver (tissue). The tissue is taken and
examined.
Also, about 30 cc (2 tablespoons) of blood will be drawn to test the blood for viruses,
including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant will
not be done because it would be too dangerous for the patient.
At least 2 weeks before the bone marrow infusion, the patient will be immunized with Prevnar
7. Prevnar 7 is a vaccine that is used in children to protect against some types of bacteria
called Streptococcus pneumoniae, which can cause the lung infection called pneumonia. People
with Sickle Cell anemia are at a higher risk of dying from an infection from this type of
bacteria. Although children are regularly given the Prevnar 7 vaccine, it is not common to
test a child's immune response to the vaccine. In this study, we will check the immune
system's response to the vaccine by drawing an extra 3 mL (less than 1 teaspoon) of blood 3
weeks after the patient gets the Prevnar 7 vaccine.
Just before the bone marrow transplant, we must kill the cells in the bone marrow that make
the abnormal red blood cells found in patients with severe thalassemia or sickle cell
disease. We will do this by using 3 drugs: busulfan, cyclophosphamide, and campath-1H.
Campath-1H is used to prevent the body from rejecting or refusing to let the donor blood
cells grow in the body. MESNA is given with the cyclophosphamide to prevent kidney damage.
Methotrexate and cyclosporin are also given to prevent graft-versus-host disease (GVHD);
methylprednisolone will be given after the bone marrow infusion if the patient develops GVHD.
A drug will also be given to prevent seizures (either dilantin or lorazepam).
Graft-versus-host disease (GVHD) is a possible side-effect of the transplant. In GVHD, some
cells in the donor marrow attack cells in the patient's body. This causes skin, liver, and
bowel problems, and may damage other parts of the body. Often, these problems are fairly
mild, but they can be severe or even cause death. Severe GVHD is likely to occur in about 10%
of patients.
After the patient gets the drug treatment, they will be given bone marrow from a brother or
sister who has healthy bone marrow that matches the patients. The healthy bone marrow will be
put into a vein (given IV) in the same way that blood transfusions are given. The marrow
cells then travel to the right places in the body, where they should grow and make new normal
blood cells.
This is the treatment schedule:
Protocol Day & Treatment:
14 or more days before the bone marrow infusion -- Prevnar 7 vaccine
10 days before the bone marrow infusion -- Begin Dilantin or Lorazepam (to prevent seizures)
9 days before the bone marrow infusion -- Busulfan
8 days before the bone marrow infusion -- Busulfan
7 days before the bone marrow infusion -- Busulfan
6 days before the bone marrow infusion -- Busulfan
5 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA
4 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA
3 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA
2 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, MESNA, and
cyclosporin
1 day before the bone marrow infusion -- DAY OF REST
Day "0" -- bone marrow infusion given
1 day after the bone marrow infusion -- Methotrexate
3 days after the bone marrow infusion -- Methotrexate
6 days after the bone marrow infusion -- Methotrexate
11 days after the bone marrow infusion -- Methotrexate
After transplant, Filgrastrim, a growth hormone for the bone marrow, may be given
intravenously (through a vein), if medically necessary.
Sometimes, the donor's bone marrow does not grow. Then, the patient would be without working
bone marrow cells. So that we will be ready to treat this problem if it happens, we will take
bone marrow from the hip bone before the patient gets the drug treatment. The patient will be
asleep (sedated) when the marrow is taken, and they will be given medicine for any pain they
have afterwards. This bone marrow will be frozen and stored or preserved. If the donor bone
marrow does not grow, we will thaw the stored marrow and put it back into the body. This
stored bone marrow should grow and produce working blood cells. If the stored bone marrow
must be given back, the disease will not be cured.
To tell whether the transplant has worked or "engrafted", we will take samples of bone marrow
(bone marrow aspirate). We will do this 3 weeks after the transplant to make sure the new
cells are beginning to grow. We will take another marrow sample at 3 months after the
transplant. We want to make sure the new cells are still growing. This test will take about
30 to 45 minutes. Because this test is painful, the patient will be given pain medicine
before, during, and after the test.
The patient will need to be in the hospital for at least 3 weeks after the transplant to make
sure the transplant has engrafted. We will do several tests (of the lung, kidney, and liver)
before and after the bone marrow transplant. We want to find out how much the treatment has
helped the patient and how much it might help other patients. Most tests will be done every
week for 4 months and at each visit to the hospital. Also, we will be looking at the immune
function. To do this, we will take about 8 ml (less than 2 teaspoonful) at 6 months, 1 year,
and 2 years after the transplant. When possible, we will take the blood from an IV line that
the patient already has. However, at times we will have to draw the blood with another needle
stick. A total amount of 200 mL (about 13 tablespoons) of blood will be collected from the
patient during the entire study.
After 4 months, if the patient's health is good, they will not need to come to the hospital
so often. The visits to the doctor should be more like they were before the bone marrow
transplant. Since problems may happen months after the transplant and this is a new way to
treat sickle cell disease and thalassemia the patient will need to have exams and blood tests
done every few months during the first and second years after their transplant. After that,
if all is well, the patient will need to be examined and have blood tests 4 times a year.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 |